Results 171 to 180 of about 147,027 (351)

Predictive Value of the Prothrombin Time-International Normalized Ratio to Albumin Ratio in the Prognosis of Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. [PDF]

Int J Gen Med, 2023
Sheng Y, Zeng Y, Luo W, Zhang X, Wang H, Jiao J.   +5 more
europepmc   +1 more source

Prothrombin Time [PDF]

, 2020
openaire   +1 more source

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study

Haemophilia, EarlyView.
ABSTRACT Background The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting for activated factor (F)VIII in people with haemophilia A (HA).
Tyler W. Buckner, Shannon L. Carpenter, Nabil Daoud, Christine L. Kempton, Lucy Lee, Lynn Malec, Thomas W. McLean, Paul Morton, Carrie O'Neill, Janice M. Staber, Michael Wang, Stacy E. Croteau, Michael Recht   +12 more
wiley   +1 more source

Prothrombin Time-International Normalized Ratio Predicts the Outcome of Atrial Fibrillation Patients Taking Rivaroxaban. [PDF]

Biomedicines, 2022
Chao TF, Chan YH, Tsai PC, Lee HF, Chang SH, Kuo CT, Lip GYH, Chen SA, Yeh YH.   +8 more
europepmc   +1 more source

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Haemophilia, EarlyView.
ABSTRACT Introduction The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. Aim To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who ...
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita   +7 more
wiley   +1 more source

Coagulation disorders after reperfusion of pancreatic allografts [PDF]

, 1993
Blumenstock, I., Büsing, M., Heimburger, N., Hopt, U. T., Jochum, Marianne, Nader, A.   +5 more
core   +1 more source

Enhancing the Evidence for Care in Underserved Bleeding Disorders Communities

Haemophilia, EarlyView.
ABSTRACT Background Major advances in haemophilia care have not translated equitably across all populations. Individuals with rare bleeding disorders (RBDs), people living in low‐ and lower‐middle‐income countries (LMICs) and women and girls with inherited bleeding disorders (WGWBD) continue to face significant diagnostic, therapeutic and research ...
Johnny Mahlangu
wiley   +1 more source

Pre‐Treatment Liver Stiffness Is a Stronger Predictor of Hepatocellular Carcinoma Development Than Post‐Treatment Liver Stiffness After Hepatitis C Virus Eradication

Hepatology Research, EarlyView.
Higher pre‐treatment liver stiffness measurement (LSM) values, rather than post‐treatment values, independently predicts hepatocellular carcinoma after hepatitis C virus eradication, underscoring the need for continued surveillance in patients with elevated baseline LSM.
Takuma Nakatsuka, Ryo Nakagomi, Keisuke Mabuchi, Yuki Matsushita, Tomoharu Yamada, Kazuya Okushin, Tatsuya Minami, Masaya Sato, Koji Uchino, Yotaro Kudo, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi   +12 more
wiley   +1 more source

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population. [PDF]

Genes (Basel), 2022
Zhang F, Mu G, Liu Z, Xie Q, Zhang H, Zhou S, Wang Z, Hu K, Wang Z, Zhao X, Cui Y, Xiang Q.   +11 more
europepmc   +1 more source

Assessment of Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen Concentration on Equine Plasma Samples following Different Storage Conditions [PDF]

, 2009
Stefania Casella, Claudia Giannetto, Francesco Fazio, Elisabetta Giudice, Giuseppe Piccione   +4 more
openalex   +1 more source